期刊文献+

CHAG与CAG预激方案治疗复发难治性急性髓系白血病的疗效比较 被引量:8

原文传递
导出
摘要 复发难治性急性髓系白血病(AML)缓解率低、病死率高。传统的FLAG方案疗效可靠,但化疗不良反应较大,同时药物价格昂贵,CAG预激方案对难治性AML有较好疗效,但对骨髓增生明显活跃的患者疗效欠佳。我们对CHAG与CAG预激方案治疗复发难治性AML的疗效进行了了比较。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第6期484-486,共3页 Chinese Journal of Hematology
基金 国家自然科学基金(81170520、81000921) 河南省卫生厅科研课题(2011010014) 河南省杰出青年基金资助课题(084100410019) 河南省医学攻关重点项目资助课题(200802016)
  • 相关文献

参考文献5

二级参考文献26

  • 1吴德沛,傅琤琤,唐晓文,孙爱宁,马骁,苗瞄,刘跃,均张日,夏学鸣.含有大剂量阿糖胞苷的联合化疗治疗难治和复发急性白血病[J].中华血液学杂志,2004,25(11):696-697. 被引量:32
  • 2薛艳萍,卞寿祥,孟庆祥,秘营昌,杨德光,张益枝,陈桂彬,李克,钱林生,郝玉书.HAD方案治疗成人急性非淋巴细胞白血病临床观察[J].中华血液学杂志,1995,16(2):59-61. 被引量:40
  • 3秘营昌,薛艳萍,俞文娟,刘世和,赵耀中,孟庆祥,卞寿庚,王建祥.HA为基础的三药方案治疗急性髓系白血病疗效分析及与染色体核型的关系[J].中华血液学杂志,2005,26(12):705-709. 被引量:19
  • 4Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony stimulation factor with low dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study.Leukemia,1995,9:10-14.
  • 5Lowenberg B, Downing JR, Burnen A. Acute myeloid leukemia. N Engl J Med, 1999, 341: 1051-1062.
  • 6Burnett AK. Tailoring the treatment of acute leukemia. Curt Opin Hematol, 1999, 6: 247-252.
  • 7Mitelman F. ISCN (1995) : An international system for human cytogenetics nomenclature. Basel: Karger, 1995.
  • 8Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into MRC AML 10 trial. Blood, 1998, 92: 2322-2333.
  • 9World Health Organization. A handbook for reporting results of cancer treatment. Geneva: WHO Publications, 1979.
  • 10Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol, 1975, 11: 511-519.

共引文献73

同被引文献72

  • 1MAIWen-yuan LINMao-fang.Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells[J].Chinese Medical Journal,2005(6):487-492. 被引量:22
  • 2周凡,刘丽梅,刘彦琴,朴瑛,刘景华,郭步云.MA和DA方案治疗急性髓系白血病临床分析[J].沈阳部队医药,2005,18(5):332-333. 被引量:1
  • 3ESTEY E. AML in older patients:are we making pro- gress[J] ? Best Pract Res Clin Haematol,2009,22 : 529-- 536.
  • 4BOCHNER T, BERDEL W E, HAFERLACH C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupEJ]. J Clin Oneol, 2009,27:61--69.
  • 5APPELBAUM F R,GUNDACKER H, HEAD D R, et al. Age and acute myeloid leukemia[J]. BIood, 2006,107: 3481--3485.
  • 6JULIUSSON G, ANTUNOVIC P, DEROLF A, et al. Age and acute myeloid leukemia: real world data on deci sion to treat and outcomes from the Swedish Acute Leu kemia Registry[J]. Blood,2009,113:4179--4187.
  • 7ZIOGAS D C, VOULGARELIS M, ZINTZARAS E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the etd- erly[J]. Clin Ther, 2011,33 : 254-- 279.
  • 8ALIBHAI S M,LEACH M,GUPTA V,et al. Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia [J]. Crit Rev Oneol Hemato, 2009,69:168--174.
  • 9LOWENBERG B, OSSENKOPPELE G J, VAN PUTTEN W,et al. High-dose daunorubicin in older pa- tients with acute myeloid leukemia[J]. N Engl J Med, 2009,361 : 1235 -- 1248.
  • 10BURNETT A K, MILLIGAN D, PRENTICE A G, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoie acid for acute myeloid leukemia and high-risk myelodyspiastic syndrome in pa- tients not considered fit for intensive treatment[J].Cancer, 2007,10911110-- 1124.

引证文献8

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部